Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
non-depolarizing neuromuscular blocker |
| gptkbp:approvalYear |
1983
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
M03AC04
|
| gptkbp:CASNumber |
64228-81-5
|
| gptkbp:chemicalFormula |
C53H72N2O12
|
| gptkbp:contraindication |
hypersensitivity to atracurium
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
20 minutes
|
| https://www.w3.org/2000/01/rdf-schema#label |
atracurium
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
blocks acetylcholine at neuromuscular junction
|
| gptkbp:metabolism |
gptkb:Hofmann_elimination
ester hydrolysis |
| gptkbp:molecularWeight |
889.16 g/mol
|
| gptkbp:pregnancyCategory |
Category C (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hypotension
bronchospasm histamine release |
| gptkbp:synonym |
atracurium besylate
tracrium |
| gptkbp:usedFor |
facilitation of endotracheal intubation
muscle relaxation during surgery |
| gptkbp:bfsParent |
gptkb:peripheral_muscle_relaxants
|
| gptkbp:bfsLayer |
8
|